

# **Leukaemia UK**

Blood cancer care and cure

**Annual Report**  
2018

## **Our Vision**

A world where a blood cancer diagnosis is not a life-changing event. We're committed to improving the lives of all families affected by leukaemia, lymphoma, myeloma and any other blood cancer, and working towards better treatments and care pathways for all.

## **Our Goals**

To invest our donated funds in areas where we can make the biggest impact, particularly in research, to families affected by leukaemia, lymphoma, myeloma and any other blood cancer.

To support those working in a haematology specialism to develop their skills and access the learning of others in the field.

To run our charity as efficiently as possible, to maximise the percentage of donations used to meet our charitable objectives.

The Trustees of Leukaemia UK are pleased to present their strategic report for the year ended 31 December 2018.

## Contents

<b>Chairman's statement</b>	<b>4</b>
<b>Chief Executive's report</b>	<b>5</b>
<b>Charitable activity 2018 and future plans</b>	<b>6</b>
1. Early Career Haematologist research grants	6
2. The Leukaemia UK Mind and Body Team	8
3. Helping Hands Grants for families in need	9
4. Funding Innovative Care	10
<b>Objectives and activities for 2019 and beyond</b>	<b>11</b>
<b>Principal risks and uncertainties</b>	<b>11</b>
<b>Trustees and governance</b>	<b>12</b>
<b>Financial review</b>	<b>13</b>
<b>Public benefit</b>	<b>14</b>
<b>Report of the Trustees</b>	<b>14</b>
<b>Financial statements</b>	<b>15</b>



## Chairman's statement



**We are proud to be a leading UK blood cancer charity dedicated to saving and improving lives, and helping families affected by leukaemia, myeloma, lymphoma and other blood cancers. We remain committed to finding kinder, more effective treatments, and transforming the care and support available.**

Last year Leukaemia UK made a significant step forward in its growth and towards meeting our ambition to make a significant difference to blood cancer treatment and care pathways. Our research portfolio was relaunched to address the needs of early career haematologists for flexible funding, and our exciting Mind and Body team at King's College Hospital was officially launched. Thanks to the commitment and efforts of our supporters our income grew to just over £500,000, setting us well on the path towards being one of the most impactful blood cancer charities in the UK.

Critically, our Trustee Board has identified the most effective ways for our funds to make the biggest possible impact, with the aim of remaining a lean and cost-effective organisation, and maintaining a clear grant investment strategy which does not duplicate the work of other organisations.

Our approach is very much to partner and collaborate within the sector, and we are pleased to be members of the Blood Cancer Alliance, as well as the APPG on Blood Cancer, to maintain that external focus. We will actively seek out organisations with common purpose and values, and foster constructive working links with them, to deliver our charitable work towards a cure and better care for all families going through blood cancer.

I am grateful to our all our supporters and volunteers who, through their dedication and generosity, make our work possible, and our independent Medical Panel for their invaluable advice and guidance in ensuring we fill an unmet need.

I have chaired the charity for almost 10 years, and am proud of the significant steps it has made, and of our exciting future plans.

**Alastair Adam**  
Leukaemia UK Chairman

## Chief Executive's report



I am pleased to report on another year of significant achievement for Leukaemia UK. We have been able to make huge strides with our charitable objectives only thanks to the generosity of our supporters, to whom we remain committed, to ensure their donations make the biggest possible impact.

Our aim remains firmly to make a difference to all families affected by any blood cancer. We believe that every person diagnosed is not just a statistic. They are a family receiving life-changing news, and every single one needs to know they will receive the best treatments available, combined with having access to emotional and psychological care to provide help at the right time in the right way for them.

I am delighted to share the significant impact our charity has made to those affected by blood cancer in 2018.

**Angela Smith-Morgan**  
CEO



# Charitable activity 2018 and future plans

## 1. Early Career Haematologist research grants

**Our focus on funding research into developing better and kinder treatments for blood cancer continues. In 2018 we launched this national grant scheme to support haematologists of the future. This unique programme has been designed to support newly-qualified staff working in a haematology specialism.**

The aim of the programme is two-fold: firstly, we want to fund promising research pathways, in anticipation of them then being leveraged by larger funders, so that Leukaemia UK acts as a catalyst to improved treatments and care pathways. Secondly, we aim to enable our haematologists of the future to build and develop their careers in the UK and become future leaders in this arena. We launched this programme following research indicating that this area, offering relatively small amounts of funding to clinicians starting out on their research careers, was undersupplied.

Our first call for applications was two times oversubscribed, with high quality applications from around the country. Following careful consideration, our Medical Panel finally awarded a total of £56,000 to six applicants, and we plan to have a further two rounds of these grant opportunities this year. This work will start largely in 2019, and we look forward to reporting on the progress made.

“



Talking about the launch of this programme, **Professor Antonio Pagliuca**, Professor of Stem Cell Transplantation at King's College London and Chair of Leukaemia UK's medical panel, said:

“This innovative programme offers flexible seed funding for haematology professionals still at an early stage in their careers, to explore novel projects, and find innovative approaches to blood cancer treatments and patient care. Leukaemia UK is a charity at the forefront of supporting best haematology care, practice and innovation so I would encourage applications from all staff who are at an early stage in their haematology career, with suggestions or proposals for interesting avenues of work.”



## Our grants portfolio

In 2018 we launched our Early Career Haematologists research grants. Applications were received for more than £87,000 but we selected four grants totalling over £50,000 which truly met our core purpose, and promised to deliver interesting near-term results. These were for:

Name	Organisation	Location	Research
Patrick Harrington	KCL / GSTT	London	Investigation of the immunological effects of Ponatinib in patients with CML
Satyen Gohil	UCL Cancer Institute	London	Investigating mechanisms of resistance to CD19 CAR-T cells using high-dimensional single cell technologies.
Francesca Kinsella	Institute of Immunology, University of Birmingham	Birmingham	High-dimensional analysis of the composition of peripheral blood stem cell donations and the impact on clinical outcome following allogeneic haemopoietic stem cell transplantation.
Kathryn Clarke	Addenbrooke's Hospital	Cambridge	Immuno-flowFISH for the assessment of chromosomal abnormalities in CLL with deletion 17p.

The medical panel also identified an unmet need in the availability of funding to allow non-clinicians, nurses, counsellors and others working in a haematology specialism, to travel to conferences to share their own research and learn from others. These were given to:

Name	Organisation	Location	Research
Haili Cui	KCL / GSTT	London	London EBMT conference submission on delayed citrate reaction after peripheral blood stem cell harvest.
Surabhi Chaturvedi	UCL Cancer Institute	London	London EBMT conference oral presentation on 'Mental health is everyone's business: addressing the psychological skills training needs of haemato-oncology research staff.

We intend to expand this important area of giving in 2019 to recognise the wide range of skilled professionals involved in today's haematology wards.



## 2. The Leukaemia UK Mind and Body Team

**In 2018 we launched our revolutionary Leukaemia UK Mind and Body Team at King's College Hospital, the first in the country to offer integrated physical and mental healthcare to people living with blood cancer.**

Our first team of dedicated counsellor and clinical psychologist support will focus on working with haematological patients. This two-year pilot will be evaluated and research outputs will be produced, which we hope will lead the way to shaping integrated emotional support in haematology care pathways.

For the first time we will be able to measure and evaluate the difference made to patient recovery and wellbeing, and we hope to prove that providing top class emotional support, as well as excellent clinical care, will make a significant difference to patients and their families.

This project will also provide us with a wide range of data, both qualitative and quantitative, that can be used for detailed research into mental health and haematological comorbidities, and which will underpin advances in service development and ultimately improvements in outcomes for patients.

“



Ghulam Mufti, Professor of Haemato-oncology at King's College Hospital, said at the launch of this programme:

**“We are extremely grateful to Leukaemia UK for all**

**the support that it has given us over the years. The implications of treatments such as chemotherapy and transplants make the patient's psychological journey huge and the Mind and Body Team's work will reflect that.”**

We are excited about the potential benefits for patients of such care and look forward to the data which will start being produced from 2019, which will help us to address these needs. This is a particularly timely change in care pathways, as the general focus on mental health in young people, and also during cancer treatment, is much more widely recognised and discussed.

### The background

Research into patient needs has clearly identified a significant unmet requirement for emotional and psychological support for patients and their families going through any blood cancer diagnosis. We approached King's College Hospital, which also has the Maudsley Institute of Psychiatry and Psychology within its King's Health Partners network. The Leukaemia UK Mind and Body team is now based at King's, operates within the haematology wards and is led by a psychiatrist, Dr Greg Shields. It will bring together the clinical care teams with appropriate and timely monitoring and evaluation of mental wellbeing.

### The benefits we expect to see include:

- Improved psychological and physiological outcomes for patients (including quality of life).
- Improved patient experience and satisfaction.
- Increased confidence and competence of staff to deliver integrated care (and related, improved staff experience and satisfaction).
- Reductions in levels of healthcare utilisation, particularly unscheduled care.
- Improvements in healthcare adherence. We would expect lower levels of missed appointments and non-compliance with medication among participants.

**We are proud to be at the forefront of developing specialist approaches for haematology patients and look forward to sharing the learning from the Leukaemia UK Mind and Body team.**



### 3. Helping Hands Grants for families in need

Every person's blood cancer journey is different. Leukaemia UK offers support to those affected by blood cancer every step of the way. A blood cancer diagnosis changes everything. Not only do people have to deal with difficult treatments and fears about their future, but often they face financial hardship as a direct result of their condition – something we cannot ignore.

Leukaemia UK's Helping Hand Fund plays a vital role in easing those unexpected money worries. By providing a one-off emergency grant of up to £500 we can offer help quickly in dealing with financial demands, allowing people with blood cancer to focus on the important things, like getting better.

#### Examples of grants given in 2018

Leukaemia UK's Trustees have always believed in alleviating some of the financial stresses brought to families by a blood cancer diagnosis. In 2018 we were able to give grants to 32 families around the UK for a total of more than £6,000. These families were referred to us from the following hospitals:

1. Arrowse Park Hospital
2. Birmingham Children's Hospital
3. Bristol Royal Infirmary
4. Doncaster Royal Infirmary
5. East Surrey Hospital
6. Freeman Hospital
7. Great Ormond Street Hospital
8. Guy's Hospital
9. King's College Hospital
10. Medway Maritime Hospital
11. Ninewells Hospital
12. Queen Elizabeth Hospital
13. Royal Liverpool Hospital
14. Royal Marsden Hospital
15. St George's Hospital
16. The Christie Hospital
17. University College Hospital
18. York District Hospital



Leukaemia UK has only been able to achieve all of this in 2018 thanks to the generosity of our supporters

## 4. Funding Innovative Care

**May 2018 saw the formal launch of the Leukaemia UK Ambulatory Care Unit at King's College Hospital London which allows people with blood cancer to have stem cell transplants as out-patients.**

This ground-breaking Unit offers stem cell transplants and chemotherapy in an out-patient setting, enabling people to stay in their own homes or in a hotel nearby rather than having to be admitted to hospital.

The unit is a pioneering approach to delivering stem cell transplants which, as an in-patient, has traditionally involved long stays in hospital with limited contact with the outside world to avoid infection.

People treated as out-patients need to fulfil certain conditions. For anyone not local to King's it is possible to stay nearby in a hotel while treatment takes place. Everyone is monitored very closely with space always kept free on a haematology ward, should any difficulties arise.

Leukaemia UK paid for the unit to be built and has also funded a part-time member of the nursing staff. Since the unit opened, hospital staff say people undergoing stem cell transplants and chemotherapy have found the procedure to be a more positive experience and have appreciated the new setting, which is light and airy and looks out towards a nearby park. The new unit has also saved the hospital more than 500 bed days in its first year of operating and represents a significant step forward in the treatment pathway for selected patients undergoing stem cell transplants.



Órla Stewart, Lead Nurse Haematology at King's College Hospital, said at its official launch:

“This unit means that patients have some sort of normality, they're not just in 'patient' mode. I hope this is the model of the future and in five years' time being treated as an outpatient for a stem cell transplant will be considered the 'normal' way of doing it.”

## Objectives and activities for 2019 and beyond

**Our aim remains to fill gaps in the availability and provision of grant investments for high quality research programmes, and we will continue to do this via our Early Career Haematologist programme. One of the measures of success for us will be the work which is then taken forward into bigger programmes funded elsewhere.**

In 2019 we will also launch our Fellowship Programme for any staff working in a haematology specialism, to enable them to access funds to travel to conferences and meetings to share their own research and learning with colleagues. This programme will be open to clinical staff including counsellors, AHPs, nurses, dieticians and social workers who work with a haematology specialism and are seeking to improve patient care pathways.

The first data from the Leukaemia UK Mind and Body team will start to be produced from mid 2019, and if we see evidence of significant patient benefit our ambition is to roll out similar programmes across the UK, building on and sharing the recommendations from this pilot.

Our challenge is to continue to identify areas of need which are unmet by other charities or organisations, which adhere to our goal of making the biggest possible difference to patients and their families. Blood cancer is life-changing, and our work would not be possible without our

army of individual fundraisers who bake, shave, paint and go many extra miles to support our charity. We are also grateful to the numerous organisations, clubs schools and, of course, Trusts who do so much for us.

“



“I’m so pleased to have had the privilege of running for Leukaemia UK to help fund the amazing work they do.”

Kenza, who ran the London Marathon 2018 **raising £3,139** for our cause.

## Principal risks and uncertainties

### Our key operational risks

- 1 Loss of charity data.** This risk is mitigated by our move this year to Office 365 cloud-based systems. Our data is secure, but accessible from anywhere, allowing our staff to work from home or other premises when necessary. We have an external firm of IT advisers who maintain our systems for us.
- 2 Reliance on key staff.** As a small team, our roles are flexible, however the loss of senior staff would have an impact.
- 3 External legislation or change.** For example, the GDPR legislation last year. We are constantly aware of external changes, and particularly with regard to our fundraising practices. We have never used aggressive fundraising tactics, and are always aware that many of our donors are family and friends of people affected by these diseases. Last year we took additional steps to protect our supporter data through updating our records, and having clear sign-up processes.

## Trustees and governance

### Trustees

The Trustees who served during this year are:

- Alastair Adam (Chair)
- Professor Tony Pagliuca (Chair of Medical Panel)
- Jonathan Neal
- Caroline Evans
- Amanda Stewart
- Luke Cripps
- Liz Pepper

### Chief Executive Officer

Angela Smith-Morgan

### Registered charity number

1150414

### Registered company number

08318908

### Independent examiners

Geoffrey Cole and Co

### Bankers

CAF Bank Ltd  
25 Kings Hill Ave  
Kings Hill,  
West Malling  
Kent, ME19 4JQ

Trustees meet four times per year and agree the broad strategy and areas of activity for the charity, including research strategy, approval of research grants recommended by the medical panel, financial planning, fundraising investment and reserves, and risk-management policies and performance.

When a vacancy occurs on the Board, the opportunity is taken to review the existing skills mix and identify specific skill sets which would strengthen the Board's overall effectiveness.

The Board operates an equal opportunities policy and Trustees recruited are required to demonstrate experience in the areas identified by the Trustees.

All Trustees give their time freely and no Trustee remuneration was paid during the year. Trustees are required to declare any conflict of interest, and withdraw from decisions when a conflict arises.

Day-to-day operations and management are delegated to the Chief Executive and senior staff, who provide regular reports to the Trustees on performance and operations.

### The charity benefits from sub-committees to advise on key areas of activity which are:

1. Finance and Risk committee
2. Nominations and Remuneration committee
3. Independent Medical Panel

Leukaemia UK is proud to have a panel of highly regarded UK haematologists advising us on our research investments. They are:


- Professor Tony Pagliuca, Professor of Stem Cell Transplantation at King's College London. He is the Medical Director for King's College Hospital, Networked Care Division and the National Clinical Lead for Regenerative Medicine, NHS England.
- Professor John Snowden, Consultant Haematologist, Director of Blood and Marrow Transplantation and Honorary Professor of Haemato-oncology & Stem Cell Transplantation Department of Haematology Sheffield Teaching Hospitals NHS Foundation Trust.
- Dr Kim Orchard MBBS, BSc, PhD, FRCP, FRCPATH, Specialist in Haematology and bone marrow transplantation at University Hospital Southampton NHS Foundation Trust.
- Dr Maria Gilleece, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust.
- Dr Sayajit Sahu, Consultant Haematologist, University Hospital Lewisham.

The charity is registered with the Fundraising Regulator, and is a member of the Blood Cancer Alliance, as well as a regular attendee of the APPG on Blood Cancer.

## Financial review

### Income

Following our successful rebranding in November 2017, the charity income has continued to show remarkable growth, to just over £500,000 this year. The income is well balanced across a range of sources, but our work is only possible thanks to our dedicated supporters and families of those affected by blood cancer, as we receive no government or statutory funding and rely 100% on voluntary income. We are inspired by our supporters who continue to work so hard to raise the necessary funds to ensure we can maximise our investment in vital research, improve care pathways for all families affected by any blood cancer, and alleviate extreme financial difficulties.



### Expenditure

Our charitable expenditure on grants rose this year to £137,000 compared to around £80,000 in 2017. Both of these figures reflect the fact that grant uptake has been slower than anticipated, so in this same period grant commitments of almost £500,000 are outstanding and this is reflected in the movement in our reserves. We will continue to invest in new Early Career applications and Conference Fellowships in 2019, but are also aiming to build sufficient reserves to invest in further Mind and Body work around the country – as we learn from the pioneering work at King’s College Hospital, and are able to benefit from the learning and patient experience feedback as the service builds momentum.

**We continue to strive to spend less than 30% of our income on non-grant giving activity, including overheads and fundraising costs.**

## Public benefit

The Trustees can confirm that they have reviewed the information contained in the Charity Commission’s guidance on public benefit and that they have complied with the Charities Act 2011 having due regard to this area.

All of our grant programmes are open to everyone regardless of race, religion, gender or age, among other factors.

## Report of the Trustees for the year ended 31 December 2018

The Trustees, who are also Directors of The Charity for the purposes of the Companies Act, present their annual report together with the financial statements for the 2018 year. The financial statements comply with the Charities Act 2011 and the Companies act 2006. And the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015.

Approved by order of the Board of Trustees on ..... / ..... / .....  
and signed on its behalf by:

.....

**A R Adam**  
Trustee





# Financial statements

for the Year Ended 31 December 2018

**REGISTERED COMPANY NUMBER: 08318908 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1150414**

**Strategic Report, Report of the Trustees and  
Unaudited Financial Statements for the Year Ended 31 December 2018  
for**

**Leukaemia UK Ltd**

**(formerly The Elimination  
of Leukaemia Fund Ltd)**

Geoffrey Cole & Co Ltd  
4 Reading Road  
Pangbourne  
Berkshire  
RG8 7LY

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Contents of the Financial Statements  
for the Year Ended 31 December 2018**

	Page
Strategic Report	1
Report of the Trustees	2
Independent Examiner's Report	3
Statement of Financial Activities	4
Statement of Financial Position	5 to 6
Statement of Cash Flows	7
Notes to the Statement of Cash Flows	8
Notes to the Financial Statements	9 to 15
Detailed Statement of Financial Activities	16 to 17

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Strategic Report  
for the Year Ended 31 December 2018**

The trustees present their strategic report for the year ended 31 December 2018.

Approved by order of the board of trustees on ..... and signed on its behalf by:

.....  
A R Adam - Trustee

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Report of the Trustees  
for the Year Ended 31 December 2018**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2018. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered Company number**

08318908 (England and Wales)

**Registered Charity number**

1150414

**Registered office**

4 Reading Road  
Pangbourne  
Reading  
Berkshire  
RG8 7LY

**Trustees**

A R Adam	Director	
Professor A Pagliuca	Director	
J Neal	Director	
Ms C Evans	Director	
Ms L Pepper	Director	
Mrs A L Stewart	Director	
Miss J R Coleman	Director	- resigned 25.10.2018
L Cripps	Director	- appointed 14.2.2018

**Independent examiner**

Geoffrey Cole & Co Ltd  
4 Reading Road  
Pangbourne  
Berkshire  
RG8 7LY

Approved by order of the board of trustees on ..... and signed on its behalf by:

.....  
A R Adam - Trustee

**Independent Examiner's Report to the Trustees of  
Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Independent examiner's report to the trustees of Leukaemia UK Ltd ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2018.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a registered member of ICAEW which is one of the listed bodies

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act;  
or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached

Geoffrey Cole  
ICAEW  
Geoffrey Cole & Co Ltd  
4 Reading Road  
Pangbourne  
Berkshire  
RG8 7LY

Date: .....



**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Statement of Financial Activities  
for the Year Ended 31 December 2018**

		Unrestricted fund	Restricted fund	2018 Total funds	2017 Total funds
	Not es	£	£	£	£
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	2	376,443	3,637	380,080	242,851
Other trading activities	3	125,414	-	125,414	74,863
Investment income	4	<u>1,806</u>	<u>-</u>	<u>1,806</u>	<u>1,269</u>
<b>Total</b>		<b>503,663</b>	<b>3,637</b>	<b>507,300</b>	<b>318,983</b>
<b>EXPENDITURE ON</b>					
Raising funds	5	52,996	-	52,996	30,552
<b>Charitable activities</b>	6				
CTU - Kings		-	-	-	2,000
Project Grants		54,918	-	54,918	442,773
Patient Aid Grants		6,450	-	6,450	1,977
Fellowships		-	-	-	514
General		128,816	-	128,816	86,626
Services in Kind		<u>-</u>	<u>-</u>	<u>-</u>	<u>60,850</u>
<b>Total</b>		<b>243,180</b>	<b>-</b>	<b>243,180</b>	<b>625,292</b>
<b>NET INCOME/(EXPENDITURE)</b>		<b>260,483</b>	<b>3,637</b>	<b>264,120</b>	<b>(306,309)</b>
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		<u>227,540</u>	<u>-</u>	<u>227,540</u>	<u>533,849</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>		<b><u>488,023</u></b>	<b><u>3,637</u></b>	<b><u>491,660</u></b>	<b><u>227,540</u></b>

The notes form part of these financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Statement of Financial Position  
At 31 December 2018**

	Not es	Unrestricted fund £	Restricted fund £	2018 Total funds £	2017 Total funds £
<b>FIXED ASSETS</b>					
Tangible assets	13	2,256	-	2,256	466
<b>CURRENT ASSETS</b>					
Debtors	14	12,258	-	12,258	7,925
Cash at bank		<u>1,069,174</u>	<u>3,637</u>	<u>1,072,811</u>	<u>892,279</u>
		1,081,432	3,637	1,085,069	900,204
<b>CREDITORS</b>					
Amounts falling due within one year	15	<u>(348,823)</u>	-	<u>(348,823)</u>	<u>(442,288)</u>
<b>NET CURRENT ASSETS</b>		<u>732,609</u>	<u>3,637</u>	<u>736,246</u>	<u>457,916</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		734,865	3,637	738,502	458,382
<b>CREDITORS</b>					
Amounts falling due after more than one year	16	<u>(246,842)</u>	-	<u>(246,842)</u>	<u>(230,842)</u>
<b>NET ASSETS</b>		<u><u>488,023</u></u>	<u><u>3,637</u></u>	<u><u>491,660</u></u>	<u><u>227,540</u></u>
<b>FUNDS</b>	17				
Unrestricted funds				488,023	227,540
Restricted funds				<u>3,637</u>	<u>-</u>
<b>TOTAL FUNDS</b>				<u><u>491,660</u></u>	<u><u>227,540</u></u>

The notes form part of these financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Statement of Financial Position - continued  
At 31 December 2018**

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2018 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The financial statements were approved by the Board of Trustees on ..... and were signed on its behalf by:

.....  
A R Adam -Trustee

.....  
J Neal -Trustee

The notes form part of these financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Statement of Cash Flows  
for the Year Ended 31 December 2018**

	Notes	2018 £	2017 £
<b>Cash flows from operating activities:</b>			
Cash generated from operations	1	<u>181,913</u>	<u>55,836</u>
<b>Net cash provided by (used in) operating activities</b>		<u>181,913</u>	<u>55,836</u>
<b>Cash flows from investing activities:</b>			
Purchase of tangible fixed assets		(3,187)	(366)
Interest received		<u>1,806</u>	<u>1,269</u>
<b>Net cash provided by (used in) investing activities</b>		<u>(1,381)</u>	<u>903</u>
<b>Change in cash and cash equivalents in the reporting period</b>		<u>180,532</u>	56,739
<b>Cash and cash equivalents at the beginning of the reporting period</b>		<u>892,279</u>	<u>835,540</u>
<b>Cash and cash equivalents at the end of the reporting period</b>		<u><u>1,072,811</u></u>	<u><u>892,279</u></u>

The notes form part of these financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Statement of Cash Flows  
for the Year Ended 31 December 2018**

**1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES**

	<b>2018</b>	2017
	£	£
<b>Net income/(expenditure) for the reporting period (as per the statement of financial activities)</b>	<b>264,120</b>	(306,309)
<b>Adjustments for:</b>		
Depreciation charges	<b>1,062</b>	254
Loss on disposal of fixed assets	<b>335</b>	-
Interest received	<b>(1,806)</b>	(1,269)
Increase in debtors	<b>(4,333)</b>	(3,454)
(Decrease)/increase in creditors	<b><u>(77,465)</u></b>	<u>366,614</u>
<b>Net cash provided by (used in) operating activities</b>	<b><u>181,913</u></b>	<u>55,836</u>

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements  
for the Year Ended 31 December 2018**

**1. ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

**Income**

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

**Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Tangible fixed assets**

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment	- 50% on cost
--------------------	---------------

**Taxation**

The charity is exempt from corporation tax on its charitable activities.

**Fund accounting**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.



**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2018**

**2. DONATIONS AND LEGACIES**

	2018	2017
	£	£
Donations	380,080	182,001
Donated services and facilities	<u>-</u>	<u>60,850</u>
	<b><u>380,080</u></b>	<b><u>242,851</u></b>

**3. OTHER TRADING ACTIVITIES**

	2018	2017
	£	£
Fundraising events	125,037	71,627
Lottery Income	<u>377</u>	<u>3,236</u>
	<b><u>125,414</u></b>	<b><u>74,863</u></b>

**4. INVESTMENT INCOME**

	2018	2017
	£	£
Deposit account interest	<u>1,806</u>	<u>1,269</u>

**5. RAISING FUNDS**

**Raising donations and legacies**

	2018	2017
	£	£
Cost of fundraising	36,500	30,552
Support costs	<u>16,496</u>	<u>-</u>
	<b><u>52,996</u></b>	<b><u>30,552</u></b>

**6. CHARITABLE ACTIVITIES COSTS**

In the year ended 31 December 2017 there were in kind donations of £60,850 this was included in Income within Donations and Legacies and as Expenditure as Services in Kind. There were no such contributions or expenses in the year ended 31 December 2018.

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2018**

**7. GRANTS PAYABLE**

	2018	2017
	£	£
CTU - Kings	-	2,000
Project Grants	<b>54,918</b>	442,773
Patient Aid Grants	<b>6,450</b>	1,977
Fellowships	-	514
	<u><b>61,368</b></u>	<u><b>447,264</b></u>

**8. SUPPORT COSTS**

	Management	Finance	Other	Governance costs	Totals
	£	£	£	£	£
Raising donations and legacies	<b>16,496</b>	-	-	-	<b>16,496</b>
General	<u><b>33,766</b></u>	<u><b>393</b></u>	<u><b>335</b></u>	<u><b>7,867</b></u>	<u><b>42,361</b></u>
	<u><b>50,262</b></u>	<u><b>393</b></u>	<u><b>335</b></u>	<u><b>7,867</b></u>	<u><b>58,857</b></u>

**9. NET INCOME/(EXPENDITURE)**

Net income/(expenditure) is stated after charging/(crediting):

	2018	2017
	£	£
Depreciation - owned assets	<b>1,062</b>	254
Deficit on disposal of fixed asset	<u><b>335</b></u>	<u>-</u>

**10. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2018 nor for the year ended 31 December 2017.

**Trustees' expenses**

There were no trustees' expenses paid for the year ended 31 December 2018 nor for the year ended 31 December 2017.

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2018**

**11. STAFF COSTS**

Staff costs for the year ended 31 December 2018 totalled £47,246.93. There were no staff costs in the year ended 31 December 2017.

The average monthly number of employees during the year was as follows:

	<b>2018</b>	2017
Administration	<u><u>2</u></u>	<u><u>-</u></u>

No employees received emoluments in excess of £60,000.

**12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted fund £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	240,851	2,000	242,851
Other trading activities	74,863	-	74,863
Investment income	<u>1,269</u>	<u>-</u>	<u>1,269</u>
<b>Total</b>	<b>316,983</b>	<b>2,000</b>	<b>318,983</b>
<b>EXPENDITURE ON</b>			
Raising funds	30,552	-	30,552
<b>Charitable activities</b>			
CTU - Kings	-	2,000	2,000
Project Grants	442,773	-	442,773
Patient Aid Grants	1,977	-	1,977
Fellowships	514	-	514
General	86,626	-	86,626
Services in Kind	<u>60,850</u>	<u>-</u>	<u>60,850</u>
<b>Total</b>	<b>623,292</b>	<b>2,000</b>	<b>625,292</b>
<b>NET INCOME/(EXPENDITURE)</b>	<b>(306,309)</b>	<b>-</b>	<b>(306,309)</b>
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	<u>533,849</u>	<u>-</u>	<u>533,849</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>	<b><u><u>227,540</u></u></b>	<b><u><u>-</u></u></b>	<b><u><u>227,540</u></u></b>

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2018**

**13. TANGIBLE FIXED ASSETS**

	<b>Computer equipment £</b>
<b>COST</b>	
At 1 January 2018	1,297
Additions	3,187
Disposals	<u>(850)</u>
At 31 December 2018	<u>3,634</u>
 <b>DEPRECIATION</b>	
At 1 January 2018	831
Charge for year	1,062
Eliminated on disposal	<u>(515)</u>
At 31 December 2018	<u>1,378</u>
 <b>NET BOOK VALUE</b>	
At 31 December 2018	<u>2,256</u>
At 31 December 2017	<u>466</u>

**14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2018</b>	<b>2017</b>
	£	£
Other debtors	<u>12,258</u>	<u>7,925</u>

**15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	<b>2018</b>	<b>2017</b>
	£	£
Trade creditors	-	26,101
Accrued expenses	5,123	1,913
Grant commitments	<u>343,700</u>	<u>414,274</u>
	<u>348,823</u>	<u>442,288</u>

**16. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR**

	<b>2018</b>	<b>2017</b>
	£	£
Grant commitments	<u>246,842</u>	<u>230,842</u>

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2018**

**17. MOVEMENT IN FUNDS**

	At 1.1.18 £	Net movement in funds £	At 31.12.18 £
<b>Unrestricted funds</b>			
General fund	227,540	260,483	488,023
<b>Restricted funds</b>			
Project Grants	-	3,637	3,637
<b>TOTAL FUNDS</b>	<u>227,540</u>	<u>264,120</u>	<u>491,660</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	503,663	(243,180)	260,483
<b>Restricted funds</b>			
Project Grants	3,637	-	3,637
<b>TOTAL FUNDS</b>	<u>507,300</u>	<u>(243,180)</u>	<u>264,120</u>

**Comparatives for movement in funds**

	At 1.1.17 £	Net movement in funds £	At 31.12.17 £
<b>Unrestricted Funds</b>			
General fund	533,849	(306,309)	227,540
<b>TOTAL FUNDS</b>	<u>533,849</u>	<u>(306,309)</u>	<u>227,540</u>

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Notes to the Financial Statements - continued  
for the Year Ended 31 December 2018**

**17. MOVEMENT IN FUNDS - continued**

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	316,983	(623,292)	(306,309)
<b>Restricted funds</b>			
Project Grants	2,000	(2,000)	-
<b>TOTAL FUNDS</b>	<u>318,983</u>	<u>(625,292)</u>	<u>(306,309)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.17 £	Net movement in funds £	At 31.12.18 £
<b>Unrestricted funds</b>			
General fund	533,849	(45,826)	488,023
<b>Restricted funds</b>			
Project Grants	-	3,637	3,637
<b>TOTAL FUNDS</b>	<u>533,849</u>	<u>(42,189)</u>	<u>491,660</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	820,646	(866,472)	(45,826)
<b>Restricted funds</b>			
Project Grants	5,637	(2,000)	3,637
<b>TOTAL FUNDS</b>	<u>826,283</u>	<u>(868,472)</u>	<u>(42,189)</u>

**18. RELATED PARTY DISCLOSURES**

There were no related party transactions for the year ended 31 December 2018.



**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2018**

	2018 £	2017 £
<b>INCOME AND ENDOWMENTS</b>		
<b>Donations and legacies</b>		
Donations	380,080	182,001
Donated services and facilities	<u>-</u>	<u>60,850</u>
	<b>380,080</b>	242,851
<b>Other trading activities</b>		
Fundraising events	125,037	71,627
Lottery Income	<u>377</u>	<u>3,236</u>
	<b>125,414</b>	74,863
<b>Investment income</b>		
Deposit account interest	<u>1,806</u>	<u>1,269</u>
<b>Total incoming resources</b>	<b>507,300</b>	318,983
<b>EXPENDITURE</b>		
<b>Raising donations and legacies</b>		
Cost of fundraising	36,500	30,552
<b>Charitable activities</b>		
Fundraising support staff	44,140	24,390
Chief executive officer	41,129	30,300
Other staff costs	464	-
Pension costs	722	-
Grants to institutions	<u>61,368</u>	<u>447,264</u>
	<b>147,823</b>	501,954
<b>Support costs</b>		
<b>Management</b>		
Rates and water	11,538	7,734
Insurance	566	224
Telephone	333	130
Postage and stationery	1,484	820
Sundries	1,073	258
IT support	3,035	951
Website and branding	16,496	11,525
Trust fundraiser	14,675	3,854
Carried forward	<b>49,200</b>	25,496

This page does not form part of the statutory financial statements

**Leukaemia UK Ltd  
(formerly The Elimination  
of Leukaemia Fund Ltd)**

**Detailed Statement of Financial Activities  
for the Year Ended 31 December 2018**

	<b>2018</b>	2017
	£	£
<b>Management</b>		
Brought forward	<b>49,200</b>	25,496
Donated services	-	60,850
Computer equipment	<u>1,062</u>	<u>254</u>
	<b>50,262</b>	86,600
<b>Finance</b>		
Bank charges	<b>393</b>	60
<b>Other</b>		
Loss on sale of tangible fixed assets	<b>335</b>	-
<b>Governance costs</b>		
Accountancy fees	<b>3,114</b>	2,716
Legal fees	<u>4,753</u>	<u>3,410</u>
	<u>7,867</u>	<u>6,126</u>
<b>Total resources expended</b>	<b>243,180</b>	625,292
	_____	_____
<b>Net income/(expenditure)</b>	<u><b>264,120</b></u>	<u>(306,309)</u>

This page does not form part of the statutory financial statements








7-14 Great Dover Street  
London, SE1 4YR

Phone: 020 7922 7982  
Email: [hello@leukaemiauk.org.uk](mailto:hello@leukaemiauk.org.uk)

[www.leukaemiauk.org.uk](http://www.leukaemiauk.org.uk)

  Leukaemia UK  @LeukUK

Registered charity: 1150414